In patients with Sjögren’s Syndrome, where the inflammatory component of the disease is more exacerbated, there is a statistically significant improvement in both signs and symptoms (p<0.05). Patients with dry eye disease treated with tivanisiran showed a statistically significant reduction in the central corneal damage (p<0.05). Sylentis has met at ARVO with recognized experts in […]
Author Archives: Manuel Simbionte
The application of SYL1801 in eye drops could be a new therapeutic option for the treatment of retinal diseases characterized by neovascular processes, as opposed to the ocular injection used in current treatments. SYL1801 administered in eye drops reduces angiogenesis (blood vessel formation) in an animal model of laser-induced neovascularization, similar to intravitreally injected anti-VEGF […]
The company will present results of the HELIX clinical trial with tivanisirán for the treatment of Dry Eye Syndrome, in which an improvement in central corneal damage and results in patients with Sjögren’s Syndrome are demonstrated. Sylentis will also present data from the development of SYL1801 for the treatment and prevention of diseases of the […]
The HELIX trial has shown improvement (p=0.035) in the reduction of central corneal staining Data will be presented to the FDA and other regulatory authorities during the second quarter of 2019 to define the regulatory strategy The results of the HELIX trial will be presented at the Annual Congress of the Association for Research in […]
Sylentis has reached the target of recruiting patients for its Phase III trial “HELIX” for the treatment of the signs and symptoms of dry eye disease. We estimate that the results of the trial will be available in the first four months of 2019. Madrid, October 19th, 2018.- Sylentis, PharmaMar Group (MSE:PHM), has announced […]
The results of SYL116011 have demonstrated that this treatment reduces the symptoms related to the allergy in 50% to 80%. The ARVO meeting has considered the poster presentation to be of scientific interest, contributing therefore to its release. Around 30% of the worldwide population show allergic symptoms and between 40-80% of them have the symptoms […]
Topical administration of siRNA could be a new therapeutic option for the treatment of degenerative illnesses of the retina that presents processes of neovascularization . Madrid, 4th of May, 2018. Within the framework of the annual meeting of the Association for Research in Vision and Ophthalmology (ARVO), that has been held from the 29th […]
The studies carried out with tivanisiran showed an improvement in the inflammatory ocular parameters, tear quality, and a reduction in ocular pain, that is associated with dry eye syndrome Madrid, May 3rd, 2018. Sylentis, Pharmaceutical Company belonging to the PharmaMar Group, has presented results from the clinical studies carried out with tivanisiran for the […]
The Company presents the preclinical and clinical results from studies of three molecules for the treatment of dry eye syndrome, macular degeneration and eye allergies. The presentation will take place in the framework of the annual meeting of the Association for Research in Vision and Ophthalmology (ARVO). That will be held from the 29th of […]
Tivanisiran is under investigation in a Phase III clinical trial, HELIX, in more than 30 European hospitals and 300 patients to determine its efficacy in dry eye syndrome Madrid, October 19th, 2017.- Sylentis, a Pharmaceutical Company of PharmaMar Group (PHM:MSE), pioneer in the development of new compounds based on genetic silencing technology through RNA […]
Español